BioTeke Multi-Drug Urine Test Cup
Bioteke Corporation (Wuxi) Co., Ltd. · Decision date Sep 10, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-09-10 for K261409, the BioTeke® Multi-Drug Urine Test Cup submitted by Bioteke Corporation (Wuxi) Co., Ltd. The submission was received 04/30/2026 as a traditional 510(k), not reviewed by a third party, and is classified under regulation 862.3100 with primary product code NFT and subsequent codes NFV, NFW, NFY, NGG, NGL, NGM, PTG, PTH and QAW. SESE denotes clearance to market, not PMA approval.
The review document describes the device as a rapid test for qualitative, simultaneous detection of drugs and drug metabolites in human urine. A related CLIA record, CR260360, lists Cannabinoids (THC) as an analyte with moderate complexity and an effective date of 09/30/2026. The source does not state which analytes beyond THC are claimed, cutoff concentrations, or performance results; those details would sit in the FDA review documents rather than the summary fields shown here.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Clinical Toxicology
- Decision date
- Sep 10, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261409
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Bioteke Corporation (Wuxi) Co., Ltd.
- Product code
- NFT
- Decision code
- SESE
- Decision date
- Sep 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Test, Amphetamine, Over The Counter.
- Applicant
- Bioteke Corporation (Wuxi) Co., Ltd.
- Product code
- NFT
- FDA device class
- 2
FDA decision timeline
K261409 received
Application receipt date recorded by FDA.
K261409 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bioteke Corporation (Wuxi) Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Wuxi
Sources and methodology
- Original FDA record: K261409
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records